2 active not recruiting, 2 recruiting, 1 completed, 1 not yet recruiting. 6 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 4 | Active not recruiting 2, Not yet recruiting 1, Recruiting 1 |
Follow NF1: new trials by email Literature Review of NF1 trials Research Report on NF1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | Johns Hopkins University | 10 | 2026-02-01 | 2026-05-08 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). Mirdametinib - NF1, Cutaneous Neurofibroma | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2024-02-12 | 2026-04-13 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors AZD6244 - Neurofibromatosis 1, Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 99 | 2011-09-21 | 2026-10-27 |
Neurofibroma, Plexiform (4) · Neurofibromatosis 1 (4) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Neoplasms (1) · Neuroblastoma (1) · Neurofibroma (1) · Neurofibromatoses (1) · Pain (1)
Neoplasms by Histologic Type (5) · Neoplasms, Nerve Tissue (5) · Nerve Sheath Neoplasms (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Neuromuscular Diseases (5) · Peripheral Nervous System Diseases (5) · Peripheral Nervous System Neoplasms (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Neoplasms (4) · Neoplastic Syndromes, Hereditary (4) · Neurocutaneous Syndromes (4) · Neurodegenerative Diseases (4)
AZD 6244 (1) · mirdametinib (1) · talimogene laherparepvec (1)
Johns Hopkins University (2) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (5) · China (2) · Spain (1)
Carlos Romo, MD (2) · Brigitte C Widemann, M.D. (1) · Sameer Farouk Sait, MD (1)
PMID 28029918, PMID 32187457, PMID 35467749, PMID 37115514, PMID 37400844, PMID 38869947, PMID 40709016, PMID 41139346, PMID 42540436